<DOC>
	<DOCNO>NCT01496352</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control , safety , tolerability , pharmacokinetic dose escalation Phase II study DFA-02 patient undergo colorectal surgery evaluate safety , tolerability pharmacokinetics DFA-02 .</brief_summary>
	<brief_title>DFA-02 Patients Undergoing Colorectal Surgery</brief_title>
	<detailed_description>Despite antibiotic prophylaxis improvement surgical technique , surgical site infection ( SSI ) still occur . DFA-02 novel bioresorbable modified release gel contain gentamicin vancomycin apply surgical incision closure prevention surgical site infection ( SSIs ) patient undergo colorectal surgery .</detailed_description>
	<mesh_term>Surgical Wound Infection</mesh_term>
	<criteria>1 . Males females 18 year age old ; 2 . If female , patient must : postmenopausal ( amenorrheic &lt; 1 year , postmenopausal status must confirm elevated follicle stimulate hormone [ FSH ] level &gt; 30 mIU/mL ; amenorrheic &gt; 1 year , FSH level require ) ; surgically sterilize ( uterus bilateral tubal ligation ) ; childbearing potential , must negative serum pregnancy test entry study , agree use adequate birth control study 30 day administration study agent . Medically acceptable contraceptive include : ( 1 ) surgical sterilization ( tubal ligation hysterectomy ) , ( 2 ) approve hormonal contraceptive ( birth control pill , patch , implant injection ) , ( 3 ) barrier method ( condom diaphragm ) use spermicide , ( 4 ) intrauterine device ( IUD ) ; 3 . BMI 2540 , inclusive ; 4 . Scheduled undergo nonemergent colorectal surgery involve laparotomy incision 7 cm great ( handassisted laparoscopic surgery allow ) . List eligible procedure : left , right transverse colectomy , segmental/sleeve leave colon resection , total abdominal colectomy ileorectal anastomosis , total abdominal colectomy ileostomy , total abdominal proctocolectomy , low anterior resection , sigmoid resection , nonemergent Hartmann 's procedure , colotomy polypectomy distal hepatic flexure , colostomy takedown laparotomy ( peristomal ) incision , ileopouch anal anastomosis , abdominal perineal resection rectum ; 5 . Willing able give inform consent ; 6 . Available evaluation baseline final evaluation 30 day post surgery . 1 . Known history hypersensitivity gentamicin vancomycin , aminoglycoside antibiotic excipients study product ( soy bean product sesame oil ) ; 2 . Emergency surgery ( urgent surgery allow informed consent obtain study procedure perform ) ; 3 . Significant concomitant surgical procedure ( Note : concomitant appendectomy , cholecystectomy , oophorectomy , liver biopsy/wedge resection allow ) ; 4 . Prior laparotomy within last 60 day plan procedure ; 5 . Planned second laparotomy colorectal surgical procedure ( e.g . colostomy ileostomy takedown ) within 30 day plan first procedure ; 6 . Expectation surgical drain place ; 7 . Preoperative sepsis , severe sepsis , septic shock ; 8 . Abdominal wall infection/surgical site infection previous laparotomy/laparoscopy reason ; 9 . Active systemic infection systemic ( oral intravenous ) antibiotic therapy within 1 week prior date surgery specify preoperative antimicrobial prophylaxis ( Note : single dose antibiotic therapy dental minor procedure allow use oral nonabsorbable antibiotic preoperative bowel decontamination ) ; 10 . Requirement gentamicin vancomycin preoperative antimicrobial prophylaxis ( Note : systemic antibiotic therapy within 72 hour surgery gentamicin vancomycin must avoid systemic antibiotic therapy time discuss Coordinating Center PI Medical Monitor ) ; 11 . Requirement concomitant use use 30 day prior Day 1 prescription OTC drug would interfere study place patient undue risk . Concurrent systemic topical use potentially neurotoxic , nephrotoxic , and/or ototoxic drug , gentamicin , cisplatin , cephaloridine , kanamycin , amikacin , polymyxin B , colistin , paromomycin , streptomycin , tobramycin , vancomycin , ethacrynic acid , furosemide , viomycin , avoid ; 12 . Preoperative evaluation suggest intraabdominal process might preclude full closure skin ; 13 . Ongoing treatment ( e.g . chemotherapy , radiation ) noncolorectal cancer ; 14 . History significant drug alcohol abuse within past year ; 15 . Serum Creatinine &gt; 1.3 mg/dL 16 . Serum Bilirubin &gt; 2.5 time upper limit normal ; 17 . History uncontrolled diabetes mellitus ( control diabetic patient whose hemoglobin A1c â‰¤ 9.0 % may include ) ; 18 . Patients immunocompromised include limited systemic corticosteroid use chemotherapy/radiation 30 day prior surgery , organ transplantation , HIV infection ( Note : inhaled corticosteroid exclusionary single dose use corticosteroid prevent PONV allow . ) ; 19 . Any clinically meaningful hearing loss ( Medical History ) ; 20 . Clinically exclusionary result clinical laboratory , ECG , physical examination include limited positive hepatitis B C HIV ; 21 . Pregnant lactating , childbearing potential practice birth control method high degree reliability ; 22 . Refusal accept medically indicate blood product ; 23 . Participation within 30 day start study experimental drug device study , currently participate study administration investigational drug device within 60 day anticipate ; 24 . Patients anterior abdominal wall mesh plan completely remove planned procedure ; 25 . Unable participate study reason opinion Principal Investigator ; 26 . Postsurgical life expectancy le 30 day , Investigator 's Sponsor 's opinion ; 27 . Expected discharge hospital le 3 day surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Surgical site infection</keyword>
	<keyword>Colorectal surgery</keyword>
</DOC>